XML 48 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Segments and Geographic Information
 3 Months Ended
Dec. 28, 2019
Segment Reporting [Abstract]  
Business Segments and Geographic Information Business Segments and Geographic Information
During the first fiscal quarter of 2020 and during fiscal 2019, the Company had five reportable segments: Diagnostics, Breast Health, GYN Surgical, Medical Aesthetics and Skeletal Health. The Company completed the sale of its Medical Aesthetics business on December 30, 2019 (the beginning of the second quarter of fiscal 2020). The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.
Identifiable assets for the five principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its five reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three months ended December 28, 2019 and December 29, 2018. Segment information is as follows:
 
Three Months Ended
 
December 28,
2019
 
December 29,
2018
Total revenues:
 
 
 
Diagnostics
$
311.5

 
$
296.6

Breast Health
331.1

 
324.7

GYN Surgical
119.1

 
108.4

Medical Aesthetics
65.3

 
79.8

Skeletal Health
23.5

 
21.2

 
$
850.5


$
830.7

Income (loss) from operations:
 
 
 
Diagnostics
$
49.5

 
$
43.3

Breast Health
93.9

 
97.8

GYN Surgical
31.5

 
27.0

Medical Aesthetics
(51.0
)
 
(25.2
)
Skeletal Health
0.9

 
(2.4
)
 
$
124.8


$
140.5

Depreciation and amortization:
 
 
 
Diagnostics
$
59.1

 
$
61.8

Breast Health
10.0

 
9.3

GYN Surgical
21.0

 
22.0

Medical Aesthetics
4.1

 
25.5

Skeletal Health
0.2

 
0.2

 
$
94.4


$
118.8

Capital expenditures:
 
 
 
Diagnostics
$
18.1

 
$
14.4

Breast Health
6.4

 
2.1

GYN Surgical
5.3

 
3.5

Medical Aesthetics
1.4

 
1.1

Skeletal Health
0.1

 
0.3

Corporate
0.2

 
1.2

 
$
31.5


$
22.6

 
 
December 28,
2019
 
September 28,
2019
Identifiable assets:
 
 
 
Diagnostics
$
2,232.9

 
$
2,276.6

Breast Health
1,199.3

 
1,127.8

GYN Surgical
1,303.4

 
1,328.6

Medical Aesthetics
132.7

 
159.3

Skeletal Health
31.7

 
27.3

Corporate
1,411.9

 
1,522.5

 
$
6,311.9

 
$
6,442.1



The Company had no customers that represented greater than 10% of consolidated revenues during the three months ended December 28, 2019 and December 29, 2018.
The Company operates in the major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 
Three Months Ended
 
 
December 28,
2019
 
December 29,
2018
 
United States
74.4
%
 
74.9
%
 
Europe
12.9
%
 
12.2
%
 
Asia-Pacific
8.3
%
 
8.4
%
 
Rest of World
4.4
%
 
4.5
%
 
 
100.0
%
 
100.0
%